Pages that link to "Item:Q70261"

The following pages link to Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261):

Displaying 50 items.

• escalation (Q133814) (← links)
• A conversation with Nancy Flournoy (Q254418) (← links)
• Information in a two-stage adaptive optimal design (Q389442) (← links)
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs (Q641145) (← links)
• A new characterization of Elfving's method for high dimensional computation (Q665037) (← links)
• A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity (Q665054) (← links)
• Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity (Q746098) (← links)
• Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
• A review of phase 2-3 clinical trial designs (Q1029784) (← links)
• trialr (Q1350867) (← links)
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials (Q1654244) (← links)
• A bargaining approach for resolving the tradeoff between beneficial and harmful drug responses (Q1784422) (← links)
• Optimal design to discriminate between rival copula models for a bivariate binary response (Q2273148) (← links)
• Correlated endpoints: simulation, modeling, and extreme correlations (Q2306891) (← links)
• Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
• Adaptive designs for selecting drug combinations based on efficacy-toxicity response (Q2475724) (← links)
• Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters (Q2475737) (← links)
• Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
• Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion (Q2893431) (← links)
• Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial (Q2931051) (← links)
• A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials (Q2958397) (← links)
• Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs (Q3013989) (← links)
• Sequential Methods in Multi-Arm Clinical Trials (Q3068083) (← links)
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
• Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405) (← links)
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
• A Bayesian Phase I/II Trial Design for Immunotherapy (Q4559685) (← links)
• Rejoinder (Q4916484) (← links)
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials (Q5050425) (← links)
• Simple benchmark for complex dose finding studies (Q5170208) (← links)
• A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies (Q5417921) (← links)
• A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology (Q5866135) (← links)
• gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials (Q6068828) (← links)
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes (Q6076490) (← links)
• Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information (Q6085905) (← links)
• A multi-armed Bayesian ordinal outcome utility-based sequential trial with a pairwise null clustering prior (Q6122036) (← links)
• TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes (Q6572287) (← links)
• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages (Q6572291) (← links)
• DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
• A seamless phase II/III design with dose optimization for oncology drug development (Q6618336) (← links)
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
• A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications (Q6622241) (← links)
• Combined criteria for dose optimisation in early phase clinical trials (Q6625215) (← links)
• Comparative review of novel model-assisted designs for phase I/II clinical trials (Q6625482) (← links)
• A Bayesian design for phase I cancer therapeutic vaccine trials (Q6625928) (← links)
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (Q6626777) (← links)
• A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253) (← links)
• A phase I--II design based on periodic and continuous monitoring of disease status and the times to toxicity and death (Q6627403) (← links)
• Hybrid design evaluating new biomarkers when there is an existing screening test (Q6627744) (← links)
• Change-point joint model for identification of plateau of activity in early phase trials (Q6627755) (← links)